Literature DB >> 30308521

Glucagon-Like Peptide-1 Modulates Cholesterol Homeostasis by Suppressing the miR-19b-Induced Downregulation of ABCA1.

Yue Yao1,2, Qiang Li1, Wei Wang1, Jinchao Zhang1, Ping Gao1, Yi Xu3,2.   

Abstract

BACKGROUND/AIMS: Abnormal regulation of cholesterol homeostasis is associated with type 2 diabetes mellitus (T2DM) and multiple other diseases. Glucagon-like peptide-1 (GLP-1) has unique effects on modulating hepatic lipid metabolism. However, the mechanism behind these is largely unknown. The aim of this study was to investigate the effects of GLP-1 on cholesterol-induced lipotoxicity in hepatocytes and examine the underlying mechanisms.
METHODS: Cell viability was determined by CCK-8. Caspase-3 detection was used to assess the effects of GLP-1 on cholesterol-induced apoptosis. TNF-α and IL-6 as the inflammatory markers were measured by ELISA. The alterations of miR-19b and ATP-binding cassette transporter A1 (ABCA1) resulting from high-fat diet/cholesterol incubation or GLP-1 were detected by real-time PCR and western blot.
RESULTS: GLP-1 markedly up-regulated the expression of ABCA1 protein, but didn't affect peroxisome proliferator-activated receptor α (PPAR-α) protein. The miR-19b levels were significantly down-regulated in GLP-1-treated groups. The inhibition and overexpression of miR-19b were established to explore the effects of a GLP-1-mediated alteration in miR-19b. Cholesterol transport assays revealed that treatment with GLP-1 alone or together with miR-19b inhibitor significantly enhanced ABCA1-dependent cholesterol efflux, resulting in reduced total cholesterol. Further, histological examination was used to detect lipid accumulation. Cholesterol significantly attenuated cell viability, promoted hepatic cell apoptosis, and facilitated lipid accumulation, and these effects could be reversed by GLP-1.
CONCLUSION: GLP-1 may affect cholesterol homeostasis by regulating the expression of miR-19b and ABCA1.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  ATP-binding cassette transporter A1; Cholesterol homeostasis; Glucagon-like peptide-1; miR-19b

Mesh:

Substances:

Year:  2018        PMID: 30308521     DOI: 10.1159/000494235

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  6 in total

Review 1.  Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension.

Authors:  Nicholas E King; Evan Brittain
Journal:  Pulm Circ       Date:  2022-01-18       Impact factor: 2.886

Review 2.  Remembering your A, B, C's: Alzheimer's disease and ABCA1.

Authors:  Cutler T Lewandowski; Megan S Laham; Gregory R J Thatcher
Journal:  Acta Pharm Sin B       Date:  2022-01-24       Impact factor: 14.903

3.  Identification of key candidate genes and pathways revealing the protective effect of liraglutide on diabetic cardiac muscle by integrated bioinformatics analysis.

Authors:  Ying Dong; Shi Yan; Guo-Yan Li; Min-Nan Wang; Lei Leng; Qiang Li
Journal:  Ann Transl Med       Date:  2020-03

4.  The Impact of Incretin-Based Medications on Lipid Metabolism.

Authors:  Habib Yaribeygi; Mina Maleki; Alexandra E Butler; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  J Diabetes Res       Date:  2021-12-29       Impact factor: 4.011

5.  Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Shinje Moon; Jibeom Lee; Hye Soo Chung; Yoon Jung Kim; Jae Myung Yu; Sung Hoon Yu; Chang-Myung Oh
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-18

6.  Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis.

Authors:  Motoyasu Kojima; Hirokazu Takahashi; Takuya Kuwashiro; Kenichi Tanaka; Hitoe Mori; Iwata Ozaki; Yoichiro Kitajima; Yayoi Matsuda; Kenji Ashida; Yuichiro Eguchi; Keizo Anzai
Journal:  Int J Mol Sci       Date:  2020-08-10       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.